Johnson & Johnson Basic EPS 2010-2024 | JNJ
Johnson & Johnson annual/quarterly basic eps history and growth rate from 2010 to 2024. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
- Johnson & Johnson basic eps for the quarter ending September 30, 2024 was $1.12, a 89.15% decline year-over-year.
- Johnson & Johnson basic eps for the twelve months ending September 30, 2024 was $6.03, a 55.69% decline year-over-year.
- Johnson & Johnson annual basic eps for 2023 was $0.014B, a 103.22% increase from 2022.
- Johnson & Johnson annual basic eps for 2022 was $0.007B, a 13.87% decline from 2021.
- Johnson & Johnson annual basic eps for 2021 was $0.008B, a 41.86% increase from 2020.
| Johnson & Johnson Annual Basic EPS |
| 2023 |
$13.88 |
| 2022 |
$6.83 |
| 2021 |
$7.93 |
| 2020 |
$5.59 |
| 2019 |
$5.72 |
| 2018 |
$5.70 |
| 2017 |
$0.48 |
| 2016 |
$6.04 |
| 2015 |
$5.56 |
| 2014 |
$5.80 |
| 2013 |
$4.92 |
| 2012 |
$3.94 |
| 2011 |
$3.54 |
| 2010 |
$4.85 |
| 2009 |
$4.45 |
| Johnson & Johnson Quarterly Basic EPS |
| 2024-09-30 |
$1.12 |
| 2024-06-30 |
$1.95 |
| 2024-03-31 |
$1.35 |
| 2023-12-31 |
$1.61 |
| 2023-09-30 |
$10.32 |
| 2023-06-30 |
$1.98 |
| 2023-03-31 |
$-0.03 |
| 2022-12-31 |
$1.34 |
| 2022-09-30 |
$1.70 |
| 2022-06-30 |
$1.83 |
| 2022-03-31 |
$1.96 |
| 2021-12-31 |
$1.81 |
| 2021-09-30 |
$1.39 |
| 2021-06-30 |
$2.38 |
| 2021-03-31 |
$2.35 |
| 2020-12-31 |
$0.66 |
| 2020-09-30 |
$1.35 |
| 2020-06-30 |
$1.38 |
| 2020-03-31 |
$2.20 |
| 2019-12-31 |
$1.53 |
| 2019-09-30 |
$0.67 |
| 2019-06-30 |
$2.11 |
| 2019-03-31 |
$1.41 |
| 2018-12-31 |
$1.13 |
| 2018-09-30 |
$1.47 |
| 2018-06-30 |
$1.47 |
| 2018-03-31 |
$1.63 |
| 2017-12-31 |
$-3.97 |
| 2017-09-30 |
$1.40 |
| 2017-06-30 |
$1.42 |
| 2017-03-31 |
$1.63 |
| 2016-12-31 |
$1.40 |
| 2016-09-30 |
$1.56 |
| 2016-06-30 |
$1.46 |
| 2016-03-31 |
$1.62 |
| 2015-12-31 |
$1.17 |
| 2015-09-30 |
$1.21 |
| 2015-06-30 |
$1.63 |
| 2015-03-31 |
$1.55 |
| 2014-12-31 |
$0.91 |
| 2014-09-30 |
$1.69 |
| 2014-06-30 |
$1.53 |
| 2014-03-31 |
$1.67 |
| 2013-12-31 |
$1.25 |
| 2013-09-30 |
$1.06 |
| 2013-06-30 |
$1.36 |
| 2013-03-31 |
$1.25 |
| 2012-12-31 |
$0.92 |
| 2012-09-30 |
$1.08 |
| 2012-06-30 |
$0.51 |
| 2012-03-31 |
$1.43 |
| 2011-12-31 |
$0.09 |
| 2011-09-30 |
$1.17 |
| 2011-06-30 |
$1.01 |
| 2011-03-31 |
$1.27 |
| 2010-12-31 |
$0.72 |
| 2010-09-30 |
$1.24 |
| 2010-06-30 |
$1.25 |
| 2010-03-31 |
$1.64 |
| 2009-12-31 |
$0.81 |
| 2009-09-30 |
$1.21 |
| 2009-06-30 |
$1.16 |
| 2009-03-31 |
$1.27 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$374.313B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
